Autolus Therapeutics PLC has reported its financial results for the second quarter ended June 30, 2025, showing a net product revenue of $20.9 million for the quarter and $29.9 million for the first six months of 2025. The company's cost of sales for the three months ended June 30, 2025, totaled $24.4 million. Research and development expenses decreased from $36.6 million to $27.4 million for the same period, while selling, general and administrative expenses increased from $21.9 million to $30.3 million.
The loss from operations for the three months ended June 30, 2025, was $61.2 million, compared to $58.9 million for the same period in 2024. The net loss for the three months ended June 30, 2025, was $47.9 million, compared to $58.3 million for the same period in 2024. The basic and diluted net loss per ordinary share for the three months ended June 30, 2025, totaled $(0.18), compared to $(0.22) for the same period in 2024.
Cash, cash equivalents, and marketable securities at June 30, 2025, totaled $454.3 million, compared to $588.0 million at December 31, 2024. The company estimates that with its current cash and cash equivalents and marketable securities, it is well capitalized to drive the launch and commercialization of its product in relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) and to obtain data in the lupus nephritis pivotal trial and multiple sclerosis phase 1 trial.
On the operational front, Autolus reported Q2 2025 net product sales of $20.9 million, with 46 centers fully activated in the U.S. as of August 12, 2025. Patient access to the company's product continues to increase, with coverage secured for greater than 90% of total U.S. medical lives. Additionally, the company recently received conditional marketing authorization from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for its product.
In terms of its pipeline, Autolus is on track to initiate a phase 2 pivotal clinical trial in lupus nephritis (LN) and a phase 1 clinical trial in progressive forms of multiple sclerosis (MS) by the end of 2025. The company also plans to dose the first patient in a phase 1 trial in AL amyloidosis by year-end 2025.
Autolus Therapeutics PLC is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T-cell therapies for the treatment of cancer and autoimmune disease. The company's approach involves engineering precisely targeted and controlled T-cell therapies designed to recognize target cells, break down their defense mechanisms, and eliminate these cells. Autolus has a marketed therapy, Aucatzyl®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors, and autoimmune diseases. Following these announcements, the company's shares moved -11.94%, and are now trading at a price of $2.175. For the full picture, make sure to review Autolus Therapeutics's 8-K report.
